Patient, disease, and transplant characteristics of the entire cohort
| Variables at diagnosis . | Entire cohort (N = 134) . |
|---|---|
| Age at diagnosis, median (min-max), y | 62.0 (20.2-75.3) |
| Age at alloHCT, median (min-max), y | 63.3 (20.5-75.8) |
| Sex, male (n = 134), n (%) | 79 (59.0) |
| Therapy-related MN (n = 134), n (%) | 51 (38.1) |
| Hemoglobin, median (min-max), g/dL | 8.80 (5.40-14.7) |
| WBC, median (min-max), ×109/L | 2.80 (0.600-192) |
| Platelets, median (min-max), ×109/L | 73.0 (6.00-596) |
| Peripheral blood blasts, median (min-max), % | 1.00 (0-96.0) |
| Peripheral blood blasts ≥5% (n = 124), n (%) | 39 (29.1) |
| BM blasts, median (min-max), % | 14.5 (0-92.0) |
| BM blasts >10% (n = 133), n (%) | 73 (54.5) |
| Abnormal karyotype (n = 128), n (%) | 118 (88.1) |
| Abnormal chromosome 5 (n = 121), n (%) | 101 (75.4) |
| Monosomy 17 (n = 130), n (%) | 25 (18.7) |
| CK (n = 132), n (%) | 108 (80.6) |
| Maximum TP53mut VAF, median (min-max) | 43.0 (1.00-96.0) |
| TP53mut VAF ≥10% (n = 127), n (%) | 107 (79.9) |
| Non-DBD mutation (n = 128), n (%) | 14 (10.4) |
| Mutations involving R175, R273, or R248 (n = 128), n (%) | 21 (15.7) |
| TP53mut MN, ICC classification (n = 134), n (%) | 103 (76.9) |
| AML with TP53mut | 48 (35.8) |
| AML/MDS with TP53mut | 14 (10.4) |
| MDS with TP53mut | 41 (30.6) |
| AML, other | 15 (11.2) |
| MDS, other | 16 (11.9) |
| DMT pre-alloHCT, n (%) | |
| Any | 122 (91.0) |
| Intensive | 55 (41.0) |
| Venetoclax based (n = 133) | 48 (35.8) |
| Variables available pre-alloHCT, n (%) | |
| CK (n = 109) | 45 (33.6) |
| BM blasts ≥5% (n = 132) | 11 (8.2) |
| MRD positive (n = 50) | 24 (17.9) |
| Any disease present (n = 133) | 86 (64.2) |
| HCT-CI ≥3 (n = 22) | 76 (62.3) |
| KPS ≥90 (n = 130) | 72 (55.4) |
| Matched donor (related/unrelated) | 112 (83.6) |
| Myeloablative conditioning (n = 133) | 36 (27.1) |
| Conditioning regimens | |
| Fludarabine/melphalan | 60 (44.8) |
| Busulfan/fludarabine | 38 (28.4) |
| Busulfan/cyclophosphamide | 11 (8.2) |
| Fludarabine/cyclophosphamide/total body irradiation ± thiotepa | 6 (4.5) |
| Fludarabine/melphalan + antithymocyte globulin/alemtuzumab | 5 (3.7) |
| Fludarabine/total body irradiation | 5 (3.7) |
| Fludarabine/BCNU/melphalan | 2 (1.5) |
| Fludarabine/melphalan/total body irradiation | 2 (1.5) |
| Others | 5 (3.7) |
| Melphalan (n = 134) | 69 (51.5) |
| Busulfan (n = 134) | 51 (38.1) |
| Myeloablative (n = 51) | 33 (64.7) |
| Cyclophosphamide (in conditioning, n = 134) | 23 (17.2) |
| Total body irradiation (n = 134) | 16 (11.9) |
| Myeloablative (n = 16) | 3 (18.8) |
| PTCy-based GVHD prophylaxis (n = 134) | 32 (23.9) |
| Variables at diagnosis . | Entire cohort (N = 134) . |
|---|---|
| Age at diagnosis, median (min-max), y | 62.0 (20.2-75.3) |
| Age at alloHCT, median (min-max), y | 63.3 (20.5-75.8) |
| Sex, male (n = 134), n (%) | 79 (59.0) |
| Therapy-related MN (n = 134), n (%) | 51 (38.1) |
| Hemoglobin, median (min-max), g/dL | 8.80 (5.40-14.7) |
| WBC, median (min-max), ×109/L | 2.80 (0.600-192) |
| Platelets, median (min-max), ×109/L | 73.0 (6.00-596) |
| Peripheral blood blasts, median (min-max), % | 1.00 (0-96.0) |
| Peripheral blood blasts ≥5% (n = 124), n (%) | 39 (29.1) |
| BM blasts, median (min-max), % | 14.5 (0-92.0) |
| BM blasts >10% (n = 133), n (%) | 73 (54.5) |
| Abnormal karyotype (n = 128), n (%) | 118 (88.1) |
| Abnormal chromosome 5 (n = 121), n (%) | 101 (75.4) |
| Monosomy 17 (n = 130), n (%) | 25 (18.7) |
| CK (n = 132), n (%) | 108 (80.6) |
| Maximum TP53mut VAF, median (min-max) | 43.0 (1.00-96.0) |
| TP53mut VAF ≥10% (n = 127), n (%) | 107 (79.9) |
| Non-DBD mutation (n = 128), n (%) | 14 (10.4) |
| Mutations involving R175, R273, or R248 (n = 128), n (%) | 21 (15.7) |
| TP53mut MN, ICC classification (n = 134), n (%) | 103 (76.9) |
| AML with TP53mut | 48 (35.8) |
| AML/MDS with TP53mut | 14 (10.4) |
| MDS with TP53mut | 41 (30.6) |
| AML, other | 15 (11.2) |
| MDS, other | 16 (11.9) |
| DMT pre-alloHCT, n (%) | |
| Any | 122 (91.0) |
| Intensive | 55 (41.0) |
| Venetoclax based (n = 133) | 48 (35.8) |
| Variables available pre-alloHCT, n (%) | |
| CK (n = 109) | 45 (33.6) |
| BM blasts ≥5% (n = 132) | 11 (8.2) |
| MRD positive (n = 50) | 24 (17.9) |
| Any disease present (n = 133) | 86 (64.2) |
| HCT-CI ≥3 (n = 22) | 76 (62.3) |
| KPS ≥90 (n = 130) | 72 (55.4) |
| Matched donor (related/unrelated) | 112 (83.6) |
| Myeloablative conditioning (n = 133) | 36 (27.1) |
| Conditioning regimens | |
| Fludarabine/melphalan | 60 (44.8) |
| Busulfan/fludarabine | 38 (28.4) |
| Busulfan/cyclophosphamide | 11 (8.2) |
| Fludarabine/cyclophosphamide/total body irradiation ± thiotepa | 6 (4.5) |
| Fludarabine/melphalan + antithymocyte globulin/alemtuzumab | 5 (3.7) |
| Fludarabine/total body irradiation | 5 (3.7) |
| Fludarabine/BCNU/melphalan | 2 (1.5) |
| Fludarabine/melphalan/total body irradiation | 2 (1.5) |
| Others | 5 (3.7) |
| Melphalan (n = 134) | 69 (51.5) |
| Busulfan (n = 134) | 51 (38.1) |
| Myeloablative (n = 51) | 33 (64.7) |
| Cyclophosphamide (in conditioning, n = 134) | 23 (17.2) |
| Total body irradiation (n = 134) | 16 (11.9) |
| Myeloablative (n = 16) | 3 (18.8) |
| PTCy-based GVHD prophylaxis (n = 134) | 32 (23.9) |
BCNU, Carmustine; HCT-CI, Hematopoietic cell transplantation comorbidity index; KPS, Karnofsky performance score; max, maximum; min, minimum; MRD, measurable residual disease; WBC, white blood cell.